EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modeling Lymphoma Angiogenesis, Lymphangiogenesis, and Vessel Co-Option, and the Effects of Inhibition of Lymphoma–Vessel Interactions with an αCD20-EndoP125A Antibody Fusion Protein

Christian Elledge, Yu Zhang, Seung-Uon Shin, Hyun-Mi Cho, Sundaram Ramakrishnan, Ankita Sankar, Jennifer R Chapman, Daniel Bilbao iD, Rathin Das, Hava Gil-Henn iD, Izidore S Lossos iD, Joseph D Rosenblatt

Cells · 2024

DOI: 10.3390/cells13221835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Christian Elledge und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Lymphangiogenesis, Neovascularization, Pathologic, Human Umbilical Vein Endothelial Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DoD, Florida Department of Health Bankhead Coley Cancer Research Program, NCI/SBIR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphoma growth, progression, and dissemination require tumor cell interaction with supporting vessels and are facilitated through tumor-promoted angiogenesis, lymphangiogenesis, and/or lymphoma vessel co-option. Vessel co-option has been shown to be responsible for tumor initiation, metastasis, and resistance to anti-angiogenic treatment but is largely uncharacterized in the setting of lymphoma. We developed an in vitro model to study lymphoma–vessel interactions and found that mantle cell lymphoma (MCL) cells co-cultured on Matrigel with human umbilical vein (HUVEC) or human lymphatic (HLEC) endothelial cells migrate to and anneal with newly formed capillary-like (CLS) or lymphatic-like (LLS) structures, consistent with lymphoma–vessel co-option. To inhibit this interaction, we constructed an antibody fusion protein, αCD20-EndoP125A, linking mutant anti-angiogenic endostatin (EndoP125A) to an αCD20-IgG1-targeting antibody. αCD20-EndoP125A inhibited both CLS and LLS formation, as well as MCL migration and vessel co-option. Lymphoma vessel co-option requires cell migration, which is regulated by chemokine–chemokine receptor interactions. CXCL12 and its receptor, CXCR4, are highly expressed by both endothelial cells forming CLS and by MCL cells during vessel co-option. αCD20-EndoP125A suppressed expression of both CXCL12 and CXCR4, which were required to facilitate CLS assembly and vessel co-option. We also tested αCD20-EndoP125A effects in vivo using an aggressive murine B cell lymphoma model, 38c13-hCD20, which demonstrated rapid growth and dissemination to tumor-draining lymph nodes (TDLNs) and the spleen, lung, and brain. The pattern of lymphoma distribution and growth within the lung was consistent with vessel co-option. As predicted by our in vitro model, αCD20-EndoP125A treatment inhibited primary tumor growth, angiogenesis, and lymphangiogenesis, and markedly reduced the number of circulating tumor cells and lymphoma dissemination to TDLNs and the lungs, spleen, and brain. αCD20-EndoP125A inhibited lymphoma vessel co-option within the lung. Marked inhibition of MCL primary tumor growth and dissemination were also seen using an MCL xenograft model. The ability of αCD20-EndoP125A to inhibit angiogenesis, lymphangiogenesis, and lymphoma vessel co-option provides a novel therapeutic approach for inhibition of lymphoma progression and dissemination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangiogenesisNeovascularization, PathologicHuman Umbilical Vein Endothelial CellsHumansAnimalsCell Line, TumorMiceCell MovementRecombinant Fusion ProteinsLymphomaReceptors, CXCR4Lymphoma, Mantle-CellAngiogenesis

Stichwörter der Autor:innen

angiogenesisantibody fusionendostatinlymphangiogenesislymphomamantle cell lymphomavessel co-option

Substanzen

Recombinant Fusion ProteinsReceptors, CXCR4

Autor:innen und Institutionen

  • Division of Hematology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Sheila & David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

ORCID-Profile: Daniel Bilbao, Hava Gil-Henn, Izidore S Lossos

Förderung

  • DoD
  • Florida Department of Health Bankhead Coley Cancer Research Program
  • NCI/SBIR
  • NCI NIH HHS

Zitieren

APA

Elledge, C., Zhang, Y., Shin, S. U., Cho, H. M., Ramakrishnan, S., Sankar, A., Chapman, J. R., Bilbao, D., Das, R., Gil-Henn, H., Lossos, I. S., & Rosenblatt, J. D. (2024). Modeling Lymphoma Angiogenesis, Lymphangiogenesis, and Vessel Co-Option, and the Effects of Inhibition of Lymphoma–Vessel Interactions with an αCD20-EndoP125A Antibody Fusion Protein. Cells. https://doi.org/10.3390/cells13221835

Vancouver

Elledge C, Zhang Y, Shin SU, Cho HM, Ramakrishnan S, Sankar A, et al. Modeling Lymphoma Angiogenesis, Lymphangiogenesis, and Vessel Co-Option, and the Effects of Inhibition of Lymphoma–Vessel Interactions with an αCD20-EndoP125A Antibody Fusion Protein. Cells. 2024. doi:10.3390/cells13221835

BibTeX
@article{Elledge2024,
  author = {Elledge, Christian and Zhang, Yu and Shin, Seung-Uon and Cho, Hyun-Mi and Ramakrishnan, Sundaram and Sankar, Ankita and Chapman, Jennifer R and Bilbao, Daniel and Das, Rathin and Gil-Henn, Hava and Lossos, Izidore S and Rosenblatt, Joseph D},
  title = {Modeling Lymphoma Angiogenesis, Lymphangiogenesis, and Vessel Co-Option, and the Effects of Inhibition of Lymphoma–Vessel Interactions with an αCD20-EndoP125A Antibody Fusion Protein},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13221835}
}
Kostenlos starten →